Danaher (NYSE:DHR) reported better-than-expected second-quarter 2026 results, with management citing accelerating core revenue growth, stronger life sciences demand and benefits from productivity initiatives, while also addressing investor concerns over delayed bioprocessing shipments.
President an
Danaher (NYSE:DHR) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial
Diversified science and technology company Danaher (NYSE:DHR) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.5% year...
Earnings are back in focus on Tuesday, with a Benzinga-selected slate including Danaher Corp. (NYSE:DHR). Options pricing reveals traders are bracing for volatility, with Annaly Capital Management (NYSE:NLY) and The Charles Schwab Corp. (NYSE:SCHW) reporting. Both stocks have seen positive analyst ratings and are trading above their 200-day moving averages.
Diversified science and technology company Danaher (NYSE:DHR) will be reporting results this Tuesday before market hours. Here’s what you need to know. Danah...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
What Happened? Shares of diversified science and technology company Danaher (NYSE:DHR) jumped 2.8% in the morning session after its recently acquired subsidi...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz...
The life sciences giant is transforming its diagnostics segment with its acquisition of Masimo Corporation, shifting from traditional laboratory testing into patient-connected, real-time data streams.
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Danaher has gotten torched over the last six months - since December 2025, its stock price has dropped 21.2% to $178.42 per share. This may have investors wo...
Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (NYSE:DHR) and its p...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Diversified science and technology company Danaher (NYSE:DHR) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.7% year on year to...
